Literature DB >> 9330467

Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii.

L Gern1, C M Hu, P Voet, P Hauser, Y Lobet.   

Abstract

Sequence variability of the outer surface protein (Osp) A among Borrelia burgdorferi sl species suggests that a monovalent OspA vaccine may not protect against the various Borrelia present in Eurasia. Here, we confirmed that a monovalent recombinant OspA (rOspA) vaccine does not protect mice against Ixodes ricinus mediated infection with B. burgdorferi ss, Borrelia garinii and Borrelia afzelii. However, when mice were vaccinated with a cocktail of various rOspA from these three species, they were protected, and all challenge ticks that fed on them were cleared of their spirochetes. These results showed that a multiple OspA antigens vaccine, compatible with human use, was very efficient at protecting mice against B. burgdorferi ss, B. garinii, and B. afzelii.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330467     DOI: 10.1016/s0264-410x(97)00066-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Transmission of Borrelia garinii OspA serotype 4 to BALB/c mice by Ixodes ricinus ticks collected in the field.

Authors:  C M Hu; B Wilske; V Fingerle; Y Lobet; L Gern
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Apodemus species mice are reservoir hosts of Borrelia garinii OspA serotype 4 in Switzerland.

Authors:  D Huegli; C M Hu; P-F Humair; B Wilske; L Gern
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 3.  Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications.

Authors:  G Wang; A P van Dam; I Schwartz; J Dankert
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 4.  Outer membrane proteins of pathogenic spirochetes.

Authors:  Paul A Cullen; David A Haake; Ben Adler
Journal:  FEMS Microbiol Rev       Date:  2004-06       Impact factor: 16.408

5.  Design and development of a novel vaccine for protection against Lyme borreliosis.

Authors:  Pär Comstedt; Markus Hanner; Wolfgang Schüler; Andreas Meinke; Urban Lundberg
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

6.  Vaccination with the variable tick protein of the relapsing fever spirochete Borrelia hermsii protects mice from infection by tick-bite.

Authors:  Benjamin J Krajacich; Job E Lopez; Sandra J Raffel; Tom G Schwan
Journal:  Parasit Vectors       Date:  2015-10-21       Impact factor: 3.876

7.  Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Authors:  Michael G Schwendinger; Maria O'Rourke; Andreas Traweger; Helga Savidis-Dacho; Andreas Pilz; Daniel Portsmouth; Ian Livey; P Noel Barrett; Brian A Crowe
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

8.  The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.

Authors:  Pär Comstedt; Wolfgang Schüler; Andreas Meinke; Urban Lundberg
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.